Table 6 An ANOVA summary for quadratic response surface models
From: In-situ gel bases ocular delivery system of Ganciclovir, in-vivo and in-vitro investigation
Foundation | Sum of square | Degree of freedom | Mean square | ‘F’- value | ‘P’- value |  |
|---|---|---|---|---|---|---|
Viscosity (cPs) | ||||||
Model | 5671.40 | 5 | 1134.28 | 181.7 | 0.0006 | Significant |
A – Concentration of poloxamer 407 | 5041.94 | 1 | 5041.94 | 807.6 | 0.0001 |  |
B – Concentration of HPMC E-50 LV | 65.01 | 1 | 65.01 | 10.41 | 0.0483 |  |
A B | 0.09 | 1 | 0.09 | 0.01 | 0.9091 | Â |
A ² | 564.14 | 1 | 564.14 | 90.37 | 0.0025 |  |
B ² | 0.211 | 1 | 0.21 | 0.03 | 0.8658 |  |
Gelation temperature (°C) |  | |||||
Model | 65.84 | 5 | 13.17 | 181.08 | 0.0006 | Significant |
A – Concentration of poloxamer 407 | 61.57 | 1 | 61.57 | 846.62 | < 0.0001 |  |
B – Concentration of HPMC E-50 LV | 0.5104 | 1 | 0.5104 | 7.02 | 0.0770 |  |
A B | 0.1681 | 1 | 0.1681 | 2.31 | 0.2258 | Â |
A ² | 3.59 | 1 | 3.59 | 49.38 | 0.0059 |  |
B ² | 0.0041 | 1 | 0.0041 | 0.0557 | 0.8286 |  |
Gelation time (Seconds) | Â | |||||
Model | 2.762 | 5 | 55230.09 | 1179.76 | < 0.0001 | Significant |
A – Concentration of poloxamer 407 | 2.743 | 1 | 2.74 | 5860.29 | < 0.0001 |  |
B – Concentration of HPMC E-50 LV | 322.67 | 1 | 322.67 | 6.89 | 0.0786 |  |
A B | 144.00 | 1 | 144.00 | 3.08 | 0.1777 | Â |
A ² | 1334.72 | 1 | 1334.72 | 28.51 | 0.0128 |  |
B ² | 0.8889 | 1 | 0.8889 | 0.0190 | 0.8991 |  |